Abstract 327P
Background
SARS-CoV-2 is a novel coronavirus of zoonotic origin that emerged in China and now is spreading worldwide. 71 838 cases have been registered in Kazakhstan. At the moment, 3 585 of which died. The risk of coronavirus infection in oncohematological patients is much higher, due to a reduced immune status and immunosuppressive therapy, which they receive, as well as comorbidity in majority of patients.
Methods
We included all consecutive adult patients with oncohematologic diseases admitted to KazIOR, the Hematology Department, with laboratory-confirmed COVID-19 infection between June 15 and July 15, 2020. A confirmed case of COVID-19 was defined by a positive result on a real-time RT-PCR assay and radiological evidence of pneumonia CT-scan.
Results
The median patient age was 49 (range, 18–81) years, 64% were male. The median duration of symptoms before the COVID-19 PCR assay was was 4 (range, 0–22) days. Multiple myeloma (MM) was eleven patients, Acute Lymphoblastic leukemia (ALL)-three patients, Non-Hodgkin lymphoma (NHL)-three patients, Hodgkin Lymphoma (HL)-five patients, Chronic Lymphocytic leukemia (CLL)-two patients. 16 from 25 patients (64%) received chemotherapy at the time of COVID-19 diagnosis, which was registered during the treatment or after that. 13 patients had clinical symptoms, such as fever (n = 56%), cough (n = 25.8%), and shortness of breath (n = 48%), twelve patients were asymptomatic. CT scan of the chest was performed in 14 patients and bilateral ground glass opacities were evident in all cases. Five patients died, among them three patients died from the acute respiratory distress syndrome (ARDS), two patients with ALL had a progression of the process during chemotherapy, which was aggravated by the ARDS syndrome and acute renal failure.
Conclusions
Despite positive COVID-19 status patients with oncohematologic diseases require urgent specific treatment. The virus SARS-CoV-2 worsens the condition of comorbid patients, the response to treatment, increases the possible emergence of resistant and refractory patients, due to the lengthening of the inter-course periods. Risk factors as older age, and comorbidities such as diabetes, hypertension, or cardiac disease can aggravate patient condition which were confirmed by scientific research data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
372P - Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study
Presenter: Ross A. Soo
Session: e-Poster Display Session
373P - Chromatin accessibility reveals potential prognostic value of the peak set associated with smoking history in patients with lung adenocarcinoma
Presenter: Jianlian Deng
Session: e-Poster Display Session
384P - BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Presenter: Stefanie Schalm
Session: e-Poster Display Session
385P - Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Presenter: Fabrice Barlesi
Session: e-Poster Display Session
386P - A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: LI Zhou
Session: e-Poster Display Session
387P - Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Presenter: Tomonori Hirashima
Session: e-Poster Display Session
388P - Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients
Presenter: Zhen Zhou
Session: e-Poster Display Session
389P - Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Presenter: Yi-Long Wu
Session: e-Poster Display Session
391P - Economic impact of next-generation sequencing (NGS) versus single-gene testing modalities to detect genomic alterations (GAs) in metastatic non-small cell lung cancer (mNSCLC) in Asia
Presenter: Herbert Loong
Session: e-Poster Display Session
392P - Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-positive non-small cell lung cancer patients with brain metastases in China
Presenter: Zhixin Qiu
Session: e-Poster Display Session